ストックスクリーナーアプリを入手
2.42
0.78%
-0.019
前日終値:
$2.439
開ける：
$2.44
24時間の取引高:
5,039
Relative Volume:
0.76
時価総額：
$3.82M
収益：
$2.54M
当期純損益:
$-4.13M
株価収益率:
-0.88
EPS:
-2.75
ネットキャッシュフロー:
$-4.11M
1週間 パフォーマンス:
-2.42%
1か月 パフォーマンス:
-28.19%
6か月 パフォーマンス:
-33.33%
1年 パフォーマンス:
-35.64%
1日の値動き範囲:
$2.3186
$2.44
1週間の範囲:
$2.3186
$2.6106
52週間の値動き範囲:
$2.20
$5.20
Xenetic Biosciences Inc Stock (XBIO) Company Profile
名前
Xenetic Biosciences Inc
セクター
電話
781-778-7720
住所
945 CONCORD ST., FRAMINGHAM, MA
XBIO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
XBIO
Xenetic Biosciences Inc
|
2.42 | 3.82M | 2.54M | -4.13M | -4.11M | -2.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
490.47 | 128.67B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
585.49 | 60.99B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
599.87 | 36.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
236.75 | 29.89B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
252.77 | 25.74B | 3.81B | -644.79M | -669.77M | -6.24 |
Xenetic Biosciences Inc Stock (XBIO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2020-01-08 | 開始されました | Maxim Group | Buy |
Xenetic Biosciences Inc (XBIO) 最新ニュース
Xenetic Biosciences Inc (NASDAQ:XBIO) Short Interest Update - Defense World
Analyzing Ampio Pharmaceuticals (NYSE:AMPE) & Xenetic Biosciences (NASDAQ:XBIO) - Defense World
Xenetic Biosciences (NASDAQ:XBIO) Earns Neutral Rating from HC Wainwright - Defense World
Xenetic Biosciences appoints new accounting firm By Investing.com - Investing.com Canada
Xenetic Biosciences appoints new accounting firm - Investing.com
Wainwright maintains Neutral on Xenetic shares after segment - Investing.com
Wainwright maintains Neutral on Xenetic shares after segment By Investing.com - Investing.com South Africa
Xenetic Biosciences, Inc. Releases Virtual Investor "What This M - GuruFocus
Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment - The Joplin Globe
Breakthrough Cancer Research: DNase I Technology Enhances CAR-T Cell Effectiveness in Melanoma - Stock Titan
XBIO stock touches 52-week low at $2.2 amid market challenges By Investing.com - Investing.com South Africa
XBIO stock touches 52-week low at $2.2 amid market challenges - Investing.com India
Press Release Distribution & PR Platform - ACCESS Newswire
Analyzing Takeda Pharmaceutical (NYSE:TAK) and Xenetic Biosciences (NASDAQ:XBIO) - Defense World
Xenetic Biosciences stock hits 52-week low at $2.7 By Investing.com - Investing.com South Africa
Xenetic Biosciences stock hits 52-week low at $2.7 - Investing.com
Xenetic Biosciences Inc (NASDAQ:XBIO) Sees Significant Drop in Short Interest - The AM Reporter
Short Interest in Xenetic Biosciences Inc (NASDAQ:XBIO) Decreases By 46.4% - Defense World
Xenetic partners with PeriNess for cancer study in Israel By Investing.com - Investing.com South Africa
Xenetic partners with PeriNess for cancer study in Israel - Investing.com Australia
Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into a Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Relapsed/Refractory Osteosarcoma and Ewing Sarcoma - standard-journal.com
Breakthrough DNase Treatment Takes Aim at Aggressive Childhood Cancers in New Trial - Stock Titan
Research Analysts Set Expectations for XBIO FY2025 Earnings - Defense World
Xenetic Biosciences (NASDAQ:XBIO) Earns “Neutral” Rating from HC Wainwright - Defense World
Analysts Offer Predictions for XBIO Q1 Earnings - Defense World
Xenetic Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Xenetic Biosciences, Inc. Reports Full Year 2024 Financial Results - guardonline.com
Short Interest in Xenetic Biosciences Inc (NASDAQ:XBIO) Expands By 29.2% - Defense World
Xenetic Biosciences Strengthens Cancer Research Pipeline While Maintaining $6.2M Cash Position - Stock Titan
Xenetic Biosciences, Inc. SEC 10-K Report - TradingView
XENETIC BIOSCIENCES Earnings Preview: Recent $XBIO Insider Trading, Hedge Fund Activity, and More - Nasdaq
Xenetic Biosciences Inc expected to post a loss of 20 cents a shareEarnings Preview - TradingView
Xenetic Biosciences, Inc. Presents Positive Preclinical Data Underscoring the Potential of DNase I as an Adjunctive Treatment to Enhance Immunotherapeutic Responses - ACCESS Newswire
Breakthrough: New DNase I Treatment Supercharges CAR T Cell Cancer Therapy Success - StockTitan
Xenetic Biosciences (XBIO) Expected to Announce Earnings on Thursday - Defense World
Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 25th Annual Global Investment Conference - ACCESS Newswire
Xenetic Biosciences, Inc. Reports Full Year 2021 Financial Results and Provides Business Update - ACCESS Newswire
Xenetic Biosciences, Inc. Announces Reverse Stock Split of Common Stock - ACCESS Newswire
Xenetic Biosciences, Inc. Announces Closing of $6.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules - ACCESS Newswire
Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting - Milton Daily Standard
Xenetic Biosciences Inc (XBIO) 財務データ
収益
当期純利益
現金流量
EPS
1.00%
大文字化:
|
ボリューム (24 時間):